IPCA LABORATORIES
|
|
BOM : 524494     NSE : IPCALAB     | |
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Average [Stock is fairly valued] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Upward Pledged Shares : None or < 25% |
Sep 06,2024 |
Price(EOD): ₹ 1,423.15
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 36,105.32 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
IPCA LABORATORIES | 3.2% | 6.1% | 66.7% |
SUN PHARMACEUTICAL INDUSTRIES | 0.4% | 5.1% | 64.6% |
CIPLA | -2.1% | 3.7% | 30.8% |
DR REDDYS LABORATORIES | -2.9% | -3.7% | 20.1% |
ZYDUS LIFESCIENCES | -1% | -13.6% | 81.7% |
DIVIS LABORATORIES | 2.1% | 3.9% | 42.8% |
FUNDAMENTAL ANALYSIS OF IPCA LABORATORIES
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF IPCA LABORATORIES
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
64.25
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 561.98 Cr
[Latest Qtr - Jun2024 - Consolidated Results ] 5.7
P/B Calculated based on Book Value of Rs 6,330.58 Cr
[Latest Year - Mar2024 - Consolidated Results ] 4.4
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 8,212.46 Cr
[Latest Qtr - Jun2024 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
75% 16% 18% |
SHARE PRICE MOMENTUM OF IPCA LABORATORIES
IPCA LABORATORIES vs SENSEX
DEBT OF IPCA LABORATORIES
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0.18 0.24 0.14 0.19 |
0.22 0.25 0.14 0.2 |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF IPCA LABORATORIES
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Dec2023 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF IPCA LABORATORIES
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
2.93% 22% 279.1% 6737.8% |
32.01% 27.58% 15.32% 19.72% |
QtrlyTrend |
8 | |
Latest Qtr: Jun2024 | ||
Quarterly Result Analysis → |
IPCA LABORATORIES related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE HEALTHCARE | 0.7% | 8.6% | 55.8% |
S&P BSE 400 MIDSMALLCAP | -0.4% | 6.3% | 50.4% |
S&P BSE MIDSMALLCAP | -0.6% | 7% | 53.1% |
S&P BSE 150 MIDCAP | -1% | 5.1% | 50.7% |
S&P BSE ALLCAP | -1.1% | 4.7% | 39.1% |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY HEALTHCARE | -0.4% | 6.4% | 52.5% |
NIFTY MID SMALL400 | -0.5% | 6.4% | 49.6% |
NIFTY PHARMA | -0.8% | 6.9% | 52.7% |
NIFTY500 MULTICAP 50:25:25 | -0.8% | 5.4% | 42.7% |
NIFTY 500 | -1.1% | 4.6% | 38.7% |
You may also like the below Video Courses
FAQ about IPCA LABORATORIES
Is IPCA LABORATORIES good for long term investment?
As on Sep 06,2024, the Fundamentals of IPCA LABORATORIES look Strong and hence it may be good for long term investment! See Financial Performance of IPCA LABORATORIES . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is IPCA LABORATORIES UnderValued or OverValued?
As on Sep 06,2024, IPCA LABORATORIES is Fairly Valued based on the estimates of intrinsic value and investors may wait for the buying opportunity once it becomes under valued!What is the Intrinsic Value of IPCA LABORATORIES ?
As on Sep 06,2024, the Intrinsic Value of IPCA LABORATORIES is Rs. 1,203.36 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 811.24
Fair Value [Median EV / Sales Model] : Rs. 1,231.33
Fair Value [Median Price / Sales Model] : Rs. 1,203.36
Estimated Median Fair Value of IPCA LABORATORIES : Rs. 1,203.36
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.